Influence of high flux hemodialysis and hemodiafiltration on curative effects and long-term survival rates of patients with end stage renal disease

Objective To explore the curative effects and long-term survival rates of high flux hemodialysis (HFHD) versus hemodiafiltration (HDF) for patients with end stage renal disease (ESRD). Methods 68 patients with ESRD treated at our hospital were randomly divided into a flux group (34 cases) and a control group (34 cases) according to their admission times. The flux group were treated with HFHD and the control group HDF. Both groups were followed up for 6 years. The levels of blood micromolecule toxins [serum creatinine (SCr) and blood urea nitrogen (BUN)], medium and large molecular toxins [β2- microglobulin (β-MG), serum intact parathyroid hormone (iPTH) ] before and 1, 3, and 6 years after the treatment, and the differences of survival rates at different stages after the treatment in the two groups were compared. Results 1 and 3 years after the treatment, there were no statistical differences in survival rates between the two groups (P > 0.05); 6 years after the treatment, the survival rate in the flux group was significantly higher than that in the control group (P 0.05). 1, 3, and 6 years after the treatment, the levels of medium and large molecular toxins were significantly lower than those before the treatment in the flux group and were in the flux group than in the control group (all P< 0.05). Conclusion HFDF can achieve better curative effect and long-term survival rate than HDF in the treatment of ESRD. Key words: HFHD; HDF; ESRD; Long-term; Survival rate